Charles River (CRL) announced a strategic collaboration with X-Chem to enhance its hit identification capabilities and accelerate the discovery of novel therapeutics. This partnership enables Charles River clients to access X-Chem’s DEL platform, which features a proprietary library of over 15B compounds. The collaboration combines Charles River’s in-house protein production and downstream assay development, along with decades of hit ID expertise, with X-Chem’s DEL platform.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River price target raised to $174 from $155 at Mizuho
- Strategic Divestiture and Value Unlocking: Charles River Labs’ Path to Growth
- Charles River, Toxys announce ReproTracker collaboration
- Charles River upgraded to Outperform from Market Perform at William Blair
- Charles River price target raised to $200 from $190 at Evercore ISI